FDA OKs New Drug for Lung Cancer With c-Met Overexpression

(MedPage Today) — The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, locally advanced, or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein…

Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/115586

Author :

Publish date : 2025-05-14 20:48:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31

FDA OKs New Drug for Lung Cancer With c-Met Overexpression

First Oral Therapy for Rare Adrenal Gland Tumors Gets Green Light From FDA

Mucus-Plugged Airways Linked to COPD Outcomes

Related Posts

Let a breakthrough in measuring body clocks ease the ills of shiftwork

COVID Infection May Ignite Dormant Cancer in Survivors, Study Says

This Severe Flu-Related Neurologic Complication Occurred Mostly in Healthy Kids

The Right to Discriminate Against a Patient

Rise in STEC Infections Linked to Food and Overseas Travel

Brain Health Benefits Evident in SNAP Participants

Let a breakthrough in measuring body clocks ease the ills of shiftwork

COVID Infection May Ignite Dormant Cancer in Survivors, Study Says

This Severe Flu-Related Neurologic Complication Occurred Mostly in Healthy Kids

The Right to Discriminate Against a Patient

Rise in STEC Infections Linked to Food and Overseas Travel

Brain Health Benefits Evident in SNAP Participants

Major healthcare equipment firm on brink of failure

Here’s Why Surgeons May Die Sooner Than Other Physicians

Categories

Archives